Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;22(2):61-66.
doi: 10.1136/ebmental-2019-300087. Epub 2019 Apr 17.

Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis

Anneka Tomlinson  1 , Orestis Efthimiou  2 , Katharine Boaden  3 , Emma New  3 , Sarah Mather  3 , Georgia Salanti  2 , Hissei Imai  4 , Yusuke Ogawa  5 , Aran Tajika  6 , Sanae Kishimoto  4 , Sino Kikuchi  4 , Astrid Chevance  7   8 , Toshi A Furukawa  4 , Andrea Cipriani  1   3
Affiliations

Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis

Anneka Tomlinson et al. Evid Based Ment Health. 2019 May.

Abstract

Introduction: We have recently compared all second-generation as well as selected first-generation antidepressants in terms of efficacy and acceptability in the acute treatment of major depression. Here we present a protocol for a network meta-analysis aimed at extending these results, updating the evidence base and comparing all second-generation as well as selected first-generation antidepressants in terms of specific adverse events and tolerability in the acute treatment of major depression in adults.

Methods and analysis: We will include all double-blind randomised controlled trials comparing one active drug with another or with placebo in the acute treatment major depression in adults. We will compare the following active agents: agomelatine, amitriptyline, bupropion, citalopram, clomipramine, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, trazodone, venlafaxine, vilazodone and vortioxetine. The main outcomes will include the total number of patients experiencing specific adverse events; experiencing serious adverse events; and experiencing at least one adverse event. Published and unpublished studies will be retrieved through relevant database searches, trial registries and websites; reference selection and data extraction will be completed by at least two independent reviewers. For each outcome we will undertake a network meta-analysis to synthesise all evidence. We will use local and global methods to evaluate consistency. We will perform all analyses in R. We will assess the quality of evidence contributing to network estimates with the Confidence in Network Meta-Analysis web application.

Discussion: This work will provide an in- depth analysis and an insight into the specific adverse events of individual antidepressants.

Ethics and dissemination: This review does not require ethical approval.

Prospero registration number: CRD42019128141.

Keywords: adult psychiatry.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SK reports grants from the Mental Health Okamoto Memorial Foundation, Pfizer Health Research Foundation and KDDI Foundation outside the submitted work. IH reports lecture fees from Mitsubishi-Tanabe and Yoshitomi. TAF reports personal fees from Meiji, Mitsubishi-Tanabe, MSD and Pfizer and a grant from Mitsubishi-Tanabe, outside the submitted work; TAF has a pending patent 2018-177688. All other authors report no conflict of interest

References

    1. GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1859–922. 10.1016/S0140-6736(18)32335-3 - DOI - PMC - PubMed
    1. Cipriani A, Furukawa TA, Salanti G, et al. . Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018;391:1357–66. 10.1016/S0140-6736(17)32802-7 - DOI - PMC - PubMed
    1. Furukawa TA, Salanti G, Atkinson LZ, et al. . Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open 2016;6:e010919. 10.1136/bmjopen-2015-010919 - DOI - PMC - PubMed
    1. Cipriani A, Salanti G, Furukawa TA, et al. . Antidepressants might work for people with major depression: where do we go from here? Lancet Psychiatry 2018;5:461–3. 10.1016/S2215-0366(18)30133-0 - DOI - PubMed
    1. Cipriani A, Furukawa TA, Salanti G, et al. . Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746–58. 10.1016/S0140-6736(09)60046-5 - DOI - PubMed

Publication types

MeSH terms

Substances